These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23130342)

  • 1. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
    Jung SI; Shin JH; Choi HJ; Ju MY; Kim SH; Lee WG; Park YJ; Lee K;
    Ann Lab Med; 2012 Nov; 32(6):426-8. PubMed ID: 23130342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.
    Ernst EJ; Yodoi K; Roling EE; Klepser ME
    Antimicrob Agents Chemother; 2002 Feb; 46(2):578-81. PubMed ID: 11796383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
    Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
    J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.
    Yoo JI; Choi CW; Lee KM; Kim YK; Kim TU; Kim EC; Joo SI; Yun SH; Lee YS; Kim BS
    Med Mycol; 2009; 47(5):554-8. PubMed ID: 18819023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    J Clin Microbiol; 2007 Nov; 45(11):3522-8. PubMed ID: 17913927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on in vitro susceptibility of Candida spp. isolated from blood culture].
    Grandesso S; Sapino B; Mazzuccato S; Solinas M; Bedin M; D'Angelo M; Gion M
    Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
    Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital.
    Passos XS; Costa CR; Araújo CR; Nascimento ES; e Souza LK; Fernandes Ode F; Sales WS; Silva Mdo R
    Mycopathologia; 2007 Mar; 163(3):145-51. PubMed ID: 17334813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.
    Bourgeois N; Dehandschoewercker L; Bertout S; Bousquet PJ; Rispail P; Lachaud L
    J Clin Microbiol; 2010 Jan; 48(1):154-61. PubMed ID: 19889902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
    Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.
    Lewis RE; Kontoyiannis DP; Darouiche RO; Raad II; Prince RA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3499-505. PubMed ID: 12384356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
    Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
    J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
    Samra Z; Yardeni M; Peled N; Bishara J
    Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.